The Prognostic Role of [ 18 F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study
Cancer Biotherapy and Radiopharmaceuticals · 2024
DOI: 10.1089/cbr.2023.0110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Luca Filippi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Baseline 2-deoxy-2[18F]fluoro-d-glucose ([18F]FDG) positron emission tomography (PET)-derived parameters and 12-week metabolic response were investigated as prognostic factors in advanced cutaneous squamous cell carcinoma (cSCC) submitted to cemiplimab immunotherapy. Materials and Methods: Clinical records of 25 cSCC patients receiving cemiplimab, submitted to [18F]FDG positron emission tomography/computed tomography (PET/CT) at baseline and after ∼12 weeks, were retrospectively reviewed. The Kaplan-Meier (KM) method was applied to analyze differences in event-free survival (EFS), and Cox regression analysis was employed to identify the prognostic factors.
Results
At the 12-week PET/CT evaluation, 16 patients (64%) were classified as responders (complete or partial response) and 9 (36%) as nonresponders ("unconfirmed progressive metabolic disease") according to immune PET Response Criteria in Solid Tumors (iPERCIST). By KM analysis, baseline metabolic tumor volume (MTV) and total lesion glycolysis (TLG) significantly correlated with the EFS (p < 0.05). Furthermore, the KM analysis showed that the lack of metabolic response at 12 weeks was associated with meaningfully shorter EFS (7.2 ± 1 months in nonresponders vs. 20.3 ± 2.3 months in responders). In Cox multivariate analysis, metabolic response at 12 weeks remained the only predictor of the EFS (p < 0.05).
Conclusions
Baseline tumor load (i.e., MTV and TLG) and metabolic response at 12 weeks may have a prognostic impact in cSCC patients treated with cemiplimab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy.
- Dermatology Unit "Daniele Innocenzi," "A. Fiorini" Hospital, Terracina, Italy.
- Department of Medico-Surgical Sciences and Biotechnologies, Pathology Unit, ICOT Hospital, University of Rome "La Sapienza," Rome, Italy.
- Nuclear Medicine Unit, Santa Maria Goretti Hospital, Latina, Italy.
- Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
ORCID-Profile: Luca Filippi
Zitieren
APA
Filippi, L., Proietti, I., Petrozza, V., Potenza, C., Bagni, O., & Schillaci, O. (2024). The Prognostic Role of [ 18 F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2023.0110
Vancouver
Filippi L, Proietti I, Petrozza V, Potenza C, Bagni O, Schillaci O. The Prognostic Role of [ 18 F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2023.0110
BibTeX
@article{Filippi2024,
author = {Filippi, Luca and Proietti, Ilaria and Petrozza, Vincenzo and Potenza, Concetta and Bagni, Oreste and Schillaci, Orazio},
title = {The Prognostic Role of [ 18 F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
doi = {10.1089/cbr.2023.0110}
}
EUVIMED